MBX Biosciences price target raised to $80 from $38 at Oppenheimer

Oppenheimer raised its price target on MBX Biosciences (MBX) to $80 from $38, maintaining an Outperform rating, following positive once-weekly canvuparatide data in adult patients with chronic hypoparathyroidism. The trial demonstrated efficacy comparable to Ascendis Pharma’s daily Yorvipath, despite using a more stringent calcium utilization bar, leading the firm to believe an attractive buying opportunity remains despite recent share price appreciation.

Analysis

MBX Biosciences (MBX) has received a significant vote of confidence from Wall Street, with Oppenheimer more than doubling its price target to $80 from $38 and Guggenheim raising its target to $84 from $44, both maintaining bullish ratings. This optimism is directly tied to positive Phase 2 clinical data for canvuparatide, the company's once-weekly treatment for chronic hypoparathyroidism. The trial demonstrated an efficacy profile comparable to Ascendis Pharma's (ASND) daily injectable, Yorvipath, a key competitive benchmark. Critically, MBX's trial employed a more stringent calcium utilization standard for measuring response, suggesting the drug's performance is particularly robust and potentially superior. Despite a significant rally in MBX shares following the announcement, Oppenheimer's commentary indicates that the market may not have fully priced in this de-risking event, framing the current valuation as an attractive buying opportunity rather than a peak.

Key Decisions for Investors

• Given the strong clinical data and substantial analyst price target upgrades, investors should evaluate MBX as a potential long position, as the positive results for canvuparatide significantly de-risk its path to market.
• Monitor the competitive dynamics with Ascendis Pharma (ASND); canvuparatide's once-weekly dosing and performance under stringent trial conditions suggest a potential best-in-class profile that could capture significant market share if approved.
• Despite the recent stock surge, consider Oppenheimer's view that an attractive buying opportunity remains, suggesting that any price consolidation could present a strategic entry point for investors with a long-term horizon.